{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:16:05Z","timestamp":1779387365898,"version":"3.53.1"},"reference-count":81,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Management of relapsed\/refractory (R\/R) classic Hodgkin lymphoma (cHL) has evolved substantially with the integration of novel targeted and immune-based therapies. Agents such as brentuximab vedotin (BV) and immune checkpoint inhibitors (CPIs) have demonstrated high response rates in multiple settings and are increasingly used as therapeutic strategies for frontline, salvage, and multiply relapsed cHL. Consequently, the traditional roles of cytotoxic chemotherapy and stem cell transplantation are being redefined, with greater emphasis on disease biology and individualized risk\u2013benefit assessment. Though data are continuing to evolve, it appears that the use of CPIs and BV can improve outcomes for patients with R\/R disease, even as retreatment, and can lead to durable remissions. This review summarizes current management paradigms for R\/R cHL and highlights emerging data regarding sequencing, retreatment, and the use of novel agents.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000827","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:15Z","timestamp":1779386415000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy"],"prefix":"10.1097","volume":"32","author":[{"given":"Kento","family":"Kawai","sequence":"first","affiliation":[{"name":"Baylor School of Medicine, Internal Residency Program, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Akkad","sequence":"additional","affiliation":[{"name":"UT MD Anderson Cancer Center Hematology\/Medical Oncology Fellowship Program, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-3990","authenticated-orcid":false,"given":"Christopher","family":"Flowers","sequence":"additional","affiliation":[{"name":"Dept of Lymphoma\/Myeloma, UT MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5]]},"reference":[{"key":"R2-20260521","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"R3-20260521","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"R4-20260521","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V96.4.1280","article-title":"Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group","volume":"96","author":"Josting","year":"2000","journal-title":"Blood"},{"key":"R5-20260521","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1200\/JCO.1990.8.7.1173","article-title":"Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin\u2019s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy","volume":"8","author":"Straus","year":"1990","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"R6-20260521","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/10428199209061558","article-title":"A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin\u2019s disease at diagnosis. Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party","volume":"7","author":"Proctor","year":"1992","journal-title":"Leuk Lymphoma"},{"key":"R7-20260521","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"R8-20260521","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"R9-20260521","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"key":"R10-20260521","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"R11-20260521","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"key":"R12-20260521","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","article-title":"Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804","volume":"18","author":"Bartlett","year":"2007","journal-title":"Ann Oncol"},{"key":"R13-20260521","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.seminhematol.2024.06.003","article-title":"The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era","volume":"61","author":"Varma","year":"2024","journal-title":"Semin Hematol"},{"key":"R14-20260521","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"key":"R15-20260521","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"key":"R16-20260521","doi-asserted-by":"crossref","first-page":"e70126","DOI":"10.1002\/hem3.70126","article-title":"Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Mei","year":"2025","journal-title":"Hemasphere"},{"key":"R17-20260521","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R18-20260521","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"key":"R19-20260521","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"key":"R20-20260521","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"R21-20260521","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R22-20260521","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1111\/bjh.70052","article-title":"Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed\/refractory classical Hodgkin lymphoma","volume":"207","author":"Lynch","year":"2025","journal-title":"Br J Haematol"},{"key":"R23-20260521","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"key":"R24-20260521","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1470-2045(18)30426-1","article-title":"Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin\u2019s lymphoma (AHOD1221): a Children\u2019s Oncology Group, multicentre single-arm, phase 1-2 trial","volume":"19","author":"Cole","year":"2018","journal-title":"Lancet Oncol"},{"key":"R25-20260521","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin\u2019s lymphoma: an international, multicentre, single-arm, phase 1-2 trial","volume":"19","author":"O'Connor","year":"2018","journal-title":"Lancet Oncol"},{"key":"R26-20260521","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.2147\/OTT.S70264","article-title":"Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma","volume":"7","author":"Gutierrez","year":"2014","journal-title":"Onco Targets Ther"},{"key":"R27-20260521","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"R28-20260521","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"R29-20260521","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"key":"R30-20260521","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2023-179573","article-title":"PD-1 blockade before autologous stem cell transplantation improves outcomes in relapsed\/refractory classic Hodgkin lymphoma: results from a multicenter cohort","volume":"142","author":"Desai","year":"2023","journal-title":"Blood"},{"key":"R31-20260521","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol"},{"key":"R32-20260521","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/hematology.2024000574","article-title":"Has PD-1 blockade changed the standard of care for cHL?","volume":"2024","author":"Kuczmarski","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R33-20260521","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"R34-20260521","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"R35-20260521","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"R36-20260521","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2019s lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"key":"R37-20260521","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol"},{"key":"R38-20260521","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC Transplant BRaVE study","volume":"106","author":"Marie Jos\u00e9 Kersten","year":"2021","journal-title":"Haematologica"},{"key":"R39-20260521","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41409-019-0454-z","article-title":"Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma","volume":"54","author":"Abuelgasim","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R40-20260521","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3324\/haematol.2015.134213","article-title":"Impact of post-brentuximab vedotin consolidation on relapsed\/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program","volume":"101","author":"Perrot","year":"2016","journal-title":"Haematologica"},{"key":"R41-20260521","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"R42-20260521","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"R43-20260521","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.3324\/haematol.2023.282780","article-title":"Effect of cumulative dose of brentuximab vedotin maintenance in relapsed\/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes","volume":"108","author":"Wagner","year":"2023","journal-title":"Haematologica"},{"key":"R44-20260521","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"R45-20260521","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood-2021-148139","article-title":"A phase II single arm study of nivolumab as maintenance therapy after autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression","volume":"138","author":"Bachier","year":"2021","journal-title":"Blood"},{"key":"R46-20260521","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol"},{"key":"R47-20260521","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdz004","article-title":"Outcomes of patients with the third or higher relapsed classical Hodgkin lymphoma: results from the German Hodgkin Study Group","volume":"30","author":"Br\u00f6ckelmann","year":"2019","journal-title":"Ann Oncol"},{"key":"R48-20260521","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"R49-20260521","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv"},{"key":"R50-20260521","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"R51-20260521","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"R52-20260521","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J Hematol Oncol"},{"key":"R53-20260521","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-025-01257-1","article-title":"Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers","volume":"15","author":"Voorhees","year":"2025","journal-title":"Blood Cancer J"},{"key":"R54-20260521","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"key":"R55-20260521","doi-asserted-by":"crossref","first-page":"e002347","DOI":"10.1136\/jitc-2021-002347","article-title":"Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R56-20260521","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1158\/1078-0432.CCR-21-0133","article-title":"Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R57-20260521","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"R58-20260521","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"R59-20260521","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"R60-20260521","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood.2023020485","article-title":"Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"key":"R61-20260521","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.2012.45.3308","article-title":"Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma","volume":"31","author":"Moskowitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"R62-20260521","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bjh.15585","article-title":"Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1\/2 clinical trial","volume":"183","author":"Budde","year":"2018","journal-title":"Br J Haematol"},{"key":"R63-20260521","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","article-title":"A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma","volume":"118","author":"Fehniger","year":"2011","journal-title":"Blood"},{"key":"R64-20260521","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ajh.21664","article-title":"A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma","volume":"85","author":"Johnston","year":"2010","journal-title":"Am J Hematol"},{"key":"R65-20260521","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2015-10-671826","article-title":"How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant","volume":"127","author":"Alinari","year":"2016","journal-title":"Blood"},{"key":"R66-20260521","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cncr.11511","article-title":"A pilot study of rituximab in patients with recurrent, classic Hodgkin disease","volume":"98","author":"Younes","year":"2003","journal-title":"Cancer"},{"key":"R67-20260521","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","article-title":"Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas\/Trasplante de Medula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"key":"R68-20260521","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdf010","article-title":"Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens","volume":"13","author":"Bertz","year":"2002","journal-title":"Ann Oncol"},{"key":"R69-20260521","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jtct.2021.12.005","article-title":"Real-world outcomes of autologous and allogeneic hematopoietic stem cell transplantation for relapsed\/refractory Hodgkin lymphoma in the era of novel therapies: a Canadian perspective","volume":"28","author":"Veilleux","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"R70-20260521","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1182\/blood-2023-182741","article-title":"Allogeneic stem cell transplantation for relapsed and\/or refractory Hodgkin lymphoma: a multicenter real world experience","volume":"142","author":"Koyun","year":"2023","journal-title":"Blood"},{"key":"R71-20260521","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/bloodadvances.2024015048","article-title":"Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma","volume":"9","author":"Tabbara","year":"2025","journal-title":"Blood Adv"},{"key":"R72-20260521","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"R73-20260521","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/hematology.2023000450","article-title":"The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure","volume":"2023","author":"Grover","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R74-20260521","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-21-2023","article-title":"Tislelizumab for relapsed\/refractory classical Hodgkin lymphoma: 3-year follow-up and correlative biomarker analysis","volume":"28","author":"Song","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R75-20260521","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R76-20260521","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"R77-20260521","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1182\/bloodadvances.2021004511","article-title":"Avelumab in relapsed\/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"key":"R78-20260521","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","article-title":"Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial","volume":"8","author":"Brudno","year":"2024","journal-title":"Blood Adv"},{"key":"R79-20260521","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"key":"R80-20260521","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1182\/blood.2024026758","article-title":"HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+ lymphoma","volume":"145","author":"Caballero","year":"2025","journal-title":"Blood"},{"key":"R81-20260521","doi-asserted-by":"crossref","first-page":"e971","DOI":"10.1097\/HS9.0000000000000971","article-title":"CAR-T cell therapy for classical Hodgkin lymphoma","volume":"7","author":"Katsin","year":"2023","journal-title":"Hemasphere"},{"key":"R82-20260521","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/bloodadvances.2023012129","article-title":"CARs for Hodgkin: engine fine-tuning is in order","volume":"8","author":"Grover","year":"2024","journal-title":"Blood Adv"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000827","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T18:00:23Z","timestamp":1779386423000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000827","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2026-01-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}